__timestamp | Pfizer Inc. |
---|---|
Monday, January 1, 2018 | 53647000000 |
Tuesday, January 1, 2019 | 51750000000 |
Wednesday, January 1, 2020 | 41908000000 |
Friday, January 1, 2021 | 81288000000 |
Saturday, January 1, 2022 | 100330000000 |
Sunday, January 1, 2023 | 58496000000 |
Unleashing the power of data
Pfizer Inc., a titan in the pharmaceutical industry, has experienced a dynamic revenue trajectory over the past five years. In 2018, Pfizer's revenue stood at approximately $53.6 billion. However, by 2020, the company faced a dip, with revenues dropping to around $41.9 billion, marking a decline of nearly 22% from 2018. This downturn was short-lived, as 2021 saw a remarkable recovery, with revenues surging by 94% to approximately $81.3 billion, largely driven by the global demand for COVID-19 vaccines. The upward trend continued into 2022, with revenues peaking at $100.3 billion, a 23% increase from the previous year. However, 2023 brought a recalibration, with revenues settling at $58.5 billion, reflecting a 42% decrease from the 2022 high. This data underscores Pfizer's resilience and adaptability in a rapidly changing global landscape.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters